Traders purchased shares of DexCom, Inc. (NASDAQ:DXCM) on weakness during trading on Thursday. $80.49 million flowed into the stock on the tick-up and $74.26 million flowed out of the stock on the tick-down, for a money net flow of $6.23 million into the stock. Of all stocks tracked, DexCom had the 28th highest net in-flow for the day. DexCom traded down ($4.00) for the day and closed at $142.16

DXCM has been the subject of a number of research analyst reports. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a report on Friday, December 28th. Oppenheimer set a $150.00 price objective on DexCom and gave the stock a “buy” rating in a report on Thursday, December 6th. Canaccord Genuity upped their price objective on DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, February 22nd. Morgan Stanley upped their price objective on DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a report on Monday, February 25th. Finally, UBS Group upped their price objective on DexCom from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, January 8th. Six investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $149.53.

The firm has a market cap of $13.22 billion, a PE ratio of 473.87 and a beta of 0.78. The company has a quick ratio of 7.32, a current ratio of 7.64 and a debt-to-equity ratio of 1.52.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.38. DexCom had a positive return on equity of 4.98% and a negative net margin of 12.32%. The firm had revenue of $338.00 million during the quarter, compared to the consensus estimate of $331.60 million. During the same period in the prior year, the firm earned $0.10 EPS. The firm’s quarterly revenue was up 52.9% compared to the same quarter last year. As a group, research analysts expect that DexCom, Inc. will post 0.46 EPS for the current year.

In related news, EVP Steven Robert Pacelli sold 3,114 shares of the stock in a transaction on Friday, December 21st. The stock was sold at an average price of $109.41, for a total value of $340,702.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Andrew K. Balo sold 10,917 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total value of $1,558,838.43. The disclosure for this sale can be found here. Over the last quarter, insiders sold 103,181 shares of company stock valued at $14,624,075. 1.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Peregrine Capital Management LLC increased its holdings in DexCom by 8.9% in the 4th quarter. Peregrine Capital Management LLC now owns 240,736 shares of the medical device company’s stock valued at $28,840,000 after purchasing an additional 19,721 shares in the last quarter. Landsberg Bennett & Dubbaneh LLC purchased a new position in DexCom in the 4th quarter valued at about $440,000. D.A. Davidson & CO. boosted its position in DexCom by 59.8% in the 4th quarter. D.A. Davidson & CO. now owns 5,642 shares of the medical device company’s stock valued at $676,000 after buying an additional 2,111 shares during the last quarter. Swiss National Bank boosted its position in DexCom by 1.0% in the 3rd quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock valued at $21,971,000 after buying an additional 1,500 shares during the last quarter. Finally, OLD National Bancorp IN boosted its position in DexCom by 3.2% in the 4th quarter. OLD National Bancorp IN now owns 11,634 shares of the medical device company’s stock valued at $1,393,000 after buying an additional 359 shares during the last quarter. Hedge funds and other institutional investors own 97.55% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2019/03/21/traders-buy-dexcom-dxcm-on-weakness.html.

DexCom Company Profile (NASDAQ:DXCM)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Tarde Deficit

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.